BIO-TECHNE Corp TECH 67.13
Health Care · NASDAQ · Data as of 2026-10-28
BIO-TECHNE Corp (TECH) has delivered +9.7% annualized revenue growth, +5.1% earnings growth, and +0.7% dividend growth over 10 years of data. Ranked #344 of 1968 stocks overall and #32 of 260 in the Health Care sector by Steady Score.
About BIO-TECHNE Corp
Company Overview
Bio-Techne develops proteins, antibodies, assays, instruments and diagnostic products for life-science research and clinical use. Scientists use its reagents to study cells, proteins and disease pathways, while automated platforms analyze biological samples. Pharmaceutical and biotechnology companies, universities and hospitals use the products in discovery, development and testing, including spatial biology, protein analysis and molecular diagnostics.
Read more
Business Model & Revenue
Revenue comes from recurring reagent and consumable sales, analytical instruments, software and diagnostic products. Protein Sciences supplies research reagents; Diagnostics and Spatial Biology provides assays and clinical or tissue-analysis tools. Instruments can create repeat demand for proprietary consumables. Research funding, biopharma activity, instrument placements and test volume drive sales, while acquisitions broaden technology and market access.
Key Facts & Market Position
The company combines a deep catalog of biological reagents with specialized analysis platforms. Quality and consistency matter because experimental results depend on reagent performance, and validated workflows can support repeat purchasing. Exposure spans early research and clinical diagnostics, but academic funding, biotech budgets and technology shifts can change demand across product lines.